RecruitingNCT06896266

Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy

Understanding and Characterizing the Genetics of Patients With Arrhythmia-Induced Cardiomyopathy


Sponsor

Hospital Universitario 12 de Octubre

Enrollment

109 participants

Start Date

Dec 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are: I. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Presence of atrial fibrillation or atrial flutter not self-limited.
  • Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) \<50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF \<50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%.
  • Signature of informed consent.
  • Ability to understand and accept participation in the study.

Exclusion Criteria14

  • Refusal of informed consent.
  • Legal or juridical incapacity.
  • Age \<18 years.
  • Life expectancy less than 1 year.
  • Impossibility of a follow-up of at least 6 months.
  • Presence of a ventricular rate \>140 beats per minute, limiting the validity of imaging measurements.
  • Presence of known factors causing systolic ventricular dysfunction:
  • Prior cardiomyopathy diagnosis.
  • Severe mitral or aortic valve disease.
  • Non-revascularizable ischemic heart disease.
  • Context of peri-resuscitation cardiopulmonary care.
  • Abusive alcohol consumption, defined as \>80 grams of ethanol or \>7 standard alcoholic beverages per day.
  • Active treatment with chemotherapeutic agents or radiation therapy to the thorax.
  • Known infection with Trypanosoma cruzi, Borrellia burgdorferi or other infectious agent causing cardiomyopathy.

Locations(4)

Ciudad Real General University Hospital

Ciudad Real, Castille-La Mancha, Spain

12 de Octubre University Hospital

Madrid, Madrid, Spain

Albacete University Hospital Complex

Albacete, Spain

Ramón y Cajal University Hospital

Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06896266


Related Trials